Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20022798 | 0.82 | GRIN2B (0.33) | BRD4GRIN2BSLC6A4SLC6A3MKNK1 | |
| SCHEMBL20022787 | 0.81 | BRD4 (0.32) | BRD4GRIN2B | |
| SCHEMBL20022802 | 0.81 | MKNK1 (0.38) | BRD4GRIN2BSLC6A4SLC6A3MKNK1 | |
| SCHEMBL20022779 | 0.78 | SMO (0.32) | GRIN2B | |
| SCHEMBL20022792 | 0.77 | RAB9A (0.36) | CASP3 | |
| SCHEMBL20022797 | 0.73 | ALDH1A1 (0.39) | BRD4GRIN2BSLC6A4SLC6A3MKNK1 | |
| SCHEMBL28461119 | 0.72 | — | — | |
| SCHEMBL20028911 | 0.68 | BRD4 (0.32) | BRD4 | |
| SCHEMBL20022794 | 0.66 | HPGD (0.35) | — | |
| SCHEMBL20028554 | 0.63 | BRD4 (0.39) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093985-A1 | Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections | MUTABILIS (FR) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093985-A1 | Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections | NQO1, PEPD, LCT | BRD4 575/4885GRIN2B 4673/4885SLC6A4 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.